Shareholder plans 4,351-share sale of common stock

Security holder Jennifer Champoux proposes to sell 4,351 shares of common stock, with an aggregate market value of $101,729.86.

Rhea-AI Filing Summary

Security holder Jennifer Champoux proposes to sell 4,351 shares of common stock, with an aggregate market value of $101,729.86. The planned sale, through UBS Financial Services on NASDAQ, is tied to a cash-funded exercise of stock options with an approximate sale date of 07/15/2026. She also reported several smaller common stock sales in May and June 2026.

Key Figures

Shares to be sold: 4,351 shares Aggregate market value: $101,729.86 Shares outstanding: 84,479,418 shares +5 more

8 metrics

Shares to be sold 4,351 shares Common stock proposed for sale by security holder

Aggregate market value $101,729.86 Aggregate market value of the 4,351 shares to be sold

Shares outstanding 84,479,418 shares Common shares outstanding referenced in the notice

Approximate sale date 07/15/2026 Approximate date for the proposed sale of common shares

Prior sale 05/22/2026 2,176 shares for $41,344.00 Common stock sold by Jennifer Champoux during past 3 months

Prior sale 05/27/2026 2,175 shares for $43,500.00 Additional common stock sale during past 3 months

Prior sale 06/17/2026 2,176 shares for $41,344.00 Common stock sale reported in the last 3 months

Prior sale 06/23/2026 2,175 shares for $43,500.00 Another common stock sale reported in the last 3 months

Key Terms

Securities To Be Sold, Securities Sold During The Past 3 Months, Exercise of stock options, Cash

4 terms

Securities To Be Sold regulatory

"144: Securities To Be Sold Common | 07/15/2026 | Exercise of stock options"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months Jennifer Champoux 321 HARRISON AVENUE"

Exercise of stock options financial

"Common | 07/15/2026 | Exercise of stock options | Issuer | | | 4351"

Cash financial

"4351 | 07/15/2026 | Cash"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GLUE shares does Jennifer Champoux plan to sell?

She plans to sell 4,351 common shares of GLUE. The proposed transaction has an aggregate market value of $101,729.86 and is expected to be executed through UBS Financial Services on NASDAQ around 07/15/2026.

What is the approximate date of the planned GLUE share sale?

The approximate date of the proposed GLUE share sale is 07/15/2026. On that date, 4,351 common shares with an aggregate market value of $101,729.86 are planned to be sold through UBS Financial Services on NASDAQ.

How were the GLUE shares to be sold by Jennifer Champoux acquired?

The 4,351 GLUE common shares are linked to an exercise of stock options on 07/15/2026. The options are to be exercised from the issuer and paid for in cash, with the resulting shares then proposed for sale.

Which broker will handle the proposed GLUE stock sale?

The proposed sale of GLUE shares will be handled by UBS Financial Services, Inc., located at 11 Madison Ave, 4th Floor, New York, NY 10010. The shares are listed for trading on NASDAQ according to the disclosure.

What GLUE share sales has Jennifer Champoux made in the past 3 months?

She reported four prior GLUE sales: 2,176 shares for $41,344.00 on 05/22/2026, 2,175 shares for $43,500.00 on 05/27/2026, plus additional identical-sized transactions on 06/17/2026 and 06/23/2026 at the same respective dollar amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 04:12 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002025233
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Monte Rosa Therapeutics, Inc.
SEC File Number	001-40522
Address of Issuer	321 HARRISON AVENUE SUITE 900 BOSTON MASSACHUSETTS 02118
Phone	617-949-2643
Name of Person for Whose Account the Securities are To Be Sold	Champoux Jennifer
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	4351	101729.86	84479418	07/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/15/2026	Exercise of stock options	Issuer			4351	07/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jennifer Champoux 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118	Common	05/22/2026	2176	41344.00
Jennifer Champoux 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118	Common	05/27/2026	2175	43500.00
Jennifer Champoux 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118	Common	06/17/2026	2176	41344.00
Jennifer Champoux 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118	Common	06/23/2026	2175	43500.00

144: Remarks and Signature

Remarks
Date of Notice	07/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Jennifer Champoux
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)